UK’s NICE recommends AbbVie’s Aquipta to treat migraines

11 Apr 2024
www.pharmaceutical-technology.com
Phase 3Drug ApprovalClinical Result
According to GlobalData, the migraine drugs market is set to be worth $18.6bn in 2030 globally. Credit: Krakenimages.com via Shutterstock.
The National Institute for Hemigraine Care Excellence (NICE) has issued a final draft guidance recommending the use of AbbVie’s migraine drug Aquipta (atogepant), for NHS use in adults in England.
AquiNational Institute for Health and Care Excellence (NICE)antagonist that is used for the prevention of both chronic AbbVieisomigraineaines. In the final draft guidance that was released on 11 April, the drug is recommended as an option for the prevention of migraines in adults who have at least four migraine days per month, only if at least three preventive medicines have failed.
Aquiptag received mcalcitonin gene-related peptide receptor antagonistalthcare products Regulatory Agency (MHRAchronic and episodic migrainespositive data from two Phase III clinical trials, ADVANCE (NCT03777059) and PROGRESS (NCT03855137), which assessed a 60mmigrainesday dose of Aquipta in adults withmigrainec and chronic migraine, respectively.
Data from both trialsshowed that Aquipta offered a substantial decline in mean monthly migraine days from baseline to 12 weeks. The treatment also provided decline from baseline in mean monthly headache days and acute medication days.Aquiptaepisodic and chronic migraine
This list price of Aquipta is £46Aquiptar 28 tablets, with the medication set to be madmigraineble on the NHS from next month. However, at first it will only be available from specialist doctorsheadachendary care settings, rather than from GPs.
See Also:Aquipta
MorphoSys gets grant for novel compounds for treating diseases associated with methyl modifying enzymes
MorphoSysios Farmaceuticos Rovi gets grant for injectable composition for treating cancer, especially breast cancer
The US Food and Drug Administration (FDA) first approved the treatment for episodic migraines in September 2021, but AbbVie expanded the drug’s label to include chronic migraines in April 2023. The drug’s European brand name is Aquipta but it is sold under the name Qulipta in Canada and the US. According to GlobalData’s Pharma Intelligence Center, Aquipta is forecast to generate $1.56bn in sales in 2030.
Migraines are intense throbbing headaches, often accompanied by symptoms like nausea, vomiting, and sensitivity to light and sound. Chronic migraines involve experiencing headaches on 15 or more days per month, with at least eight of those headaches meeting the criteria for migraine. Episodic migraines, on the other hand, occur less frequently, typically fewer than 15 days per month. Distinct migraine attacks last four to 72 hours if left untreated. According to GlobalData, the migraine market is set to be worth $18.6bn in 2030 globally.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.